24 Search Results for "CBD"

Marijuana-derived Drug Expecting Schedule II or III Drug Classification from FDA and DEA

In late June 2018, the Food and Drug Administration (FDA) approved Epidiolex for sale in the U.S. It is the first prescription drug derived from the marijuana plant. The drug is designed to treat seizures for two rare forms of epilepsy: Dravet Syndrome and Lennox-Gastaut Syndrome. “Fast-track” designation was given to the drug during its approval process because it was the first FDA approval of a drug for the treatment of patients with Dravet Syndrome.1 “Orphan drug” designation (special status given to a drug that treats a rare condition or disease) was also given to the drug for use as a treatment for both Dravet Syndrome and Lennox-Gastaut Syndrome.

https://disa.com/news/marijuana-derived-drug-expecting-schedule-ii-or-iii-drug-classification-from-fda-and-dea

DISA's Most Impactful Articles from 2018

DISA Global Solutions would like to start 2019 with a quick look back on some of our most impactful articles from 2018. With the constant changing of marijuana laws state-by state and the continued rise of the opioid epidemic, the drug testing industry was busy keeping up with all the changes. DISA is focused on helping employers maintain best practices that provide protection for their companies and ensure a safer workplace. In 2018, we addressed a number of growing industry issues, trends, and news across drug testing, background screening, and transportation topics.

https://disa.com/news/most-impactful-articles-from-2018

Day with DISA 2019 – An Employee Screening Conference for Safety-Sensitive Companies

Last year DISA Global Solutions hosted its first ‘Day with DISA’ conference and networking event. With more than 400 attendees from 260 different companies the event became the second largest drug testing conference in the U.S. This free-to-attend conference focused on marijuana drug testing and hosted experts from across the industry for eight sessions ranging from “State Marijuana Laws and Litigation Strategies” to “Emerging Technologies” to “Designing a Program that Works with Your Marijuana Laws”.

https://disa.com/news/day-with-disa-2019-an-employee-screening-conference-for-safety-sensitive-companies

Understanding the DOT’s Drug & Alcohol Regulations

On October 29, 2018, DISA Global Solutions hosted its very first ‘Day with DISA’ conference. This drug testing symposium helped educate employers on trending topics in the industry that directly impact workplace safety and compliance. Employers who comply with the Department of Transportation (DOT) for their business have specific guidelines and policies that they must follow, which often contradict or cause confusion with the everchanging marijuana legalization laws which vary by state. The symposium helped to address and clarify topics that the DOT specifies, while also clarifying the differences laws with non-DOT employees versus DOT employees. 

https://disa.com/news/dot-drug-alcohol-regulations

TO FIND OUT HOW DISA CAN IMPROVE YOUR WORKPLACE SAFETY, MAINTAIN INDUSTRY COMPLIANCE STANDARDS, AND ENSURE COMPLIANCE POLICIES, CALL DISA TODAY AT 281-673-2530.